T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers
T cell-derived cancers are hallmarked by heterogeneity, aggressiveness, and poor clinical outcomes. Available targeted therapies are severely limited due to a lack of target antigens that allow discrimination of malignant from healthy T cells. Here, we report a novel approach for the treatment of T ...
Saved in:
| Main Authors: | Katrin Schoenfeld, Jan Habermann, Philipp Wendel, Julia Harwardt, Evelyn Ullrich, Harald Kolmar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329924000924 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01) -
Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01) -
Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01) -
T-cell receptor and B-cell receptor repertoires profiling in pleural tuberculosis
by: Fengjiao Du, et al.
Published: (2024-11-01) -
Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity
by: Maya Haus-Cohen, et al.
Published: (2024-11-01)